Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-β

Virology

Volumn 402, Issue 1, 2010, Pages 121-128

  Bentz, Gretchen L ^b   Liu, Renshui ^b   Hahn, Angela M ^c   Shackelford, Julia ^b   Pagano, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF WEST FLORIDA   (United States)

Author keywords

Antiviral response; BRLF1; Epstein Barr virus; Immune response; Interferon Regulatory Factor; IRF3; IRF5; IRF7; Rta; Type I interferons

Indexed keywords

BETA INTERFERON; IMMEDIATE EARLY PROTEIN BZLF1; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; PROTEIN BRLF1; UNCLASSIFIED DRUG; VIRUS PROTEIN; AVIAN PROTEIN; BRLF1 PROTEIN, HUMAN HERPESVIRUS 4; IMMEDIATE EARLY PROTEIN; INTERFERON REGULATORY FACTOR; IRF 3 PROTEIN, GALLUS GALLUS; IRF-3 PROTEIN, GALLUS GALLUS; IRF7 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE INDUCTION; GENETIC TRANSCRIPTION; HERPES VIRUS; IMMUNOBLOTTING; INNATE IMMUNITY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY; PROTEIN ANALYSIS; SENDAI VIRUS;

HUMAN HERPESVIRUS 4; SENDAI VIRUS;

AVIAN PROTEINS; CELL LINE; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERFERON REGULATORY FACTOR-7; INTERFERON REGULATORY FACTORS; INTERFERON-BETA; NUCLEAR LOCALIZATION SIGNALS; PROTEIN INTERACTION MAPPING; SENDAI VIRUS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 77952577450     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.03.014     Document Type: Article

References (69)

1. Abate D.A., Watanabe S., Mocarski E.S. Major human cytomegalovirus structural protein pp 65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 2004, 78(20):10995-11006.
2. Abele R., Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004, 19:216-224.
3. Adamson A.L., Darr D., Holley-Guthrie E., Johnson R.A., Mauser A., Swenson J., Kenney S. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 2000, 74(3):1224-1233.
4. Baril M., Racine M.-E., Penin F., Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis c virus NS3/4A protease. J. Virol. 2009, 83(3):1299-1311.
5. Barnes B., Lubyova B., Pitha P.M. On the role of IRF in host defense. J. Interferon Cytokine Res. 2002, 22(1):59-71.
6. Barnes B.J., Richards J., Mancl M., Hanash S., Beretta L., Pitha P.M. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J. Biol. Chem. 2004, 279(43):45194-45207.
7. Basler C.F., Mikulasova A., Martinez-Sobrido L., Paragas J., Muhlberger E., Bray M., Klenk H.D., Palese P., Garcia-Sastre A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77(14):7945-7956.
8. Chang L.K., Lee Y.H., Cheng T.S., Hong Y.R., Lu P.J., Wang J.J., Wang W.H., Kuo C.W., Li S.S., Liu S.T. Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. J. Biol. Chem. 2004, 279(37):38803-38812.
9. Darr C.D., Mauser A., Kenney S. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 2001, 75(13):6135-6142.
10. Eason D.D., Shepherd A.T., Blanck G. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochim. Biophys. Acta 1999, 1446(1-2):140-144.
11. Eidson K.M., Hobbs W.E., Manning B.J., Carlson P., DeLuca N.A. Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection. J. Virol. 2002, 76(5):2180-2191.
12. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300(5622):1145-1148.
13. Fu X.Y., Schindler C., Improta T., Aebersold R., Darnell J.E. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(16):7840-7843.
14. Gershburg E., Hong K., Pagano J.S. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob. Agents Chemother. 2004, 48(5):1900-1903.
15. Grandvaux N., tenOever B.R., Servant M.J., Hiscott J. The interferon antiviral response: from viral invasion to evasion. Curr. Opin. Infect. Dis. 2002, 15(3):259-267.
16. Hahn A.M., Huye L.E., Ning S., Webster-Cyriaque J., Pagano J.S. Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J. Virol. 2005, 79(15):10040-10052.
17. Harle P., Sainz B., Carr D.J., Halford W.P. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta. Virology 2002, 293(2):295-304.
18. Hartman A.L., Bird B.H., Towner J.S., Antoniadou Z.-A., Zaki S.R., Nichol S.T. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J. Virol. 2008, 82(6):2699-2704.
19. Hartman A.L., Bird B.H., Towner J.S., Antoniadou Z.A., Zaki S.R., Nichol S.T. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J. Virol. 2008, 82(6):2699-2704.
20. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6(9):644-658.
21. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434(7034):772-777.
22. Honda K., Takaoka A., Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25(3):349-360.
23. Hsu T.Y., Chang Y., Wang P.W., Liu M.Y., Chen M.R., Chen J.Y., Tsai C.H. Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal. J. Gen. Virol. 2005, 86(Pt 2):317-322.
24. Improta T., Schindler C., Horvath C.M., Kerr I.M., Stark G.R., Darnell J.E. Transcription factor ISGF-3 formation requires phosphorylated Stat91 protein, but Stat113 protein is phosphorylated independently of Stat91 protein. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(11):4776-4780.
25. Jaworska J., Gravel A., Fink K., Grandvaux N., Flamand L. Inhibition of transcription of the beta interferon gene by the human herpesvirus 6 immediate-early 1 protein. J. Virol. 2007, 81(11):5737-5748.
26. Kenney S., Holley-Guthrie E., Mar E.C., Smith M. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 1989, 63(9):3878-3883.
27. Li Y., Webster-Cyriaque J., Tomlinson C.C., Yohe M., Kenney S. Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. J. Virol. 2004, 78(8):4197-4206.
28. Lin R., Genin P., Mamane Y., Hiscott J. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 2000, 20(17):6342-6353.
29. Lin R., Noyce R.S., Collins S.E., Everett R.D., Mossman K.L. The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. J. Virol. 2004, 78(4):1675-1684.
30. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 1998, 161(4):1947-1953.
31. Malmgaard L. Induction and regulation of IFNs during viral infections. J. Interferon. Cytokine Res. 2004, 24(8):439-454.
32. Manet E., Rigolet A., Gruffat H., Giot J.F., Sergeant A. Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. Nucleic Acids Res. 1991, 19(10):2661-2667.
33. Manet E., Allera C., Gruffat H., Mikaelian I., Rigolet A., Sergeant A. The acidic activation domain of the Epstein-Barr virus transcription factor R interacts in vitro with both TBP and TFIIB and is cell-specifically potentiated by a proline-rich region. Gene Expr. 1993, 3(1):49-59.
34. Means R.E., Choi J.K., Nakamura H., Chung Y.H., Ishido S., Jung J.U. Immune evasion strategies of Kaposi's sarcoma-associated herpesvirus. Curr. Top. Microbiol. Immunol. 2002, 269:187-201.
35. Melroe G.T., DeLuca N.A., Knipe D.M. Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J. Virol. 2004, 78(16):8411-8420.
36. Melroe G.T., Silva L., Schaffer P.A., Knipe D.M. Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: potential role in blocking IFN-beta induction. Virology 2007, 360(2):305-321.
37. Miller D.M., Cebulla C.M., Sedmak D.D. Human cytomegalovirus inhibition of major histocompatibility complex transcription and interferon signal transduction. Curr. Top. Microbiol. Immunol. 2002, 269:153-170.
38. Myskiw C., Arsenio J., van Bruggen R., Deschambault Y., Cao J. Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-{kappa}B, and IRF3 pathways. J. Virol. 2009, 83(13):6757-6768.
39. Nguyen H., Hiscott J., Pitha P.M. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 1997, 8(4):293-312.
40. Ning S., Hahn A.M., Huye L.E., Pagano J.S. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J. Virol. 2003, 77(17):9359-9368.
41. Ning S., Huye L.E., Pagano J.S. Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. J. Virol. 2005, 79(18):11671-11676.
42. Ning S., Huye L.E., Pagano J.S. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling. J. Biol. Chem. 2005, 280(13):12262-12270.
43. Paun A., Pitha P.M. The IRF family, revisited. Biochimie 2007, 89(6-7):744-753.
44. Pollara G., Katz D.R., Chain B.M. The host response to herpes simplex virus infection. Curr. Opin. Infect. Dis. 2004, 17(3):199-203.
45. Quinlivan E.B., Holley-Guthrie E.A., Norris M., Gutsch D., Bachenheimer S.L., Kenney S.C. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 1993, 21(14):1999-2007.
46. Ragoczy T., Miller G. Role of the Epstein-Barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J. Virol. 1999, 73(12):9858-9866.
47. Ragoczy T., Heston L., Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 1998, 72(10):7978-7984.
48. Saira K., Zhou Y., Jones C. The infected cell protein 0 encoded by bovine herpesvirus 1 (bICP0) induces degradation of interferon response factor 3 and, consequently, inhibits beta interferon promoter activity. J. Virol. 2007, 81(7):3077-3086.
49. Saira K., Zhou Y., Jones C. The infected cell protein 0 encoded by bovine herpesvirus 1 (bICP0) associates with interferon regulatory factor 7 and consequently inhibits beta interferon promoter activity. J. Virol. 2009, 83(8):3977-3981.
50. Sakaguchi S., Negishi H., Asagiri M., Nakajima C., Mizutani T., Takaoka A., Honda K., Taniguchi T. Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta gene expression and endotoxin shock. Biochem. Biophys. Res. Commun. 2003, 306(4):860-866.
51. Schroder M., Bowie A.G. An arms race: innate antiviral responses and counteracting viral strategies. Biochem. Soc. Trans. 2007, 35(Pt 6):1512-1514.
52. Sen G.C., Sarkar S.N. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr. Top. Microbiol. Immunol. 2007, 316:233-250.
53. Severa M., Fitzgerald K.A. TLR-mediated activation of type I IFN during antiviral immune responses: fighting the battle to win the war. Curr. Top. Microbiol. Immunol. 2007, 316:167-192.
54. Smirnova I.V., Bittel D.C., Ravindra R., Jiang H., Andrews G.K. Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1. J. Biol. Chem. 2000, 275(13):9377-9384.
55. Takada K., Ono Y. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 1989, 63(1):445-449.
56. Takaoka A., Yanai H., Kondo S., Duncan G., Negishi H., Mizutani T., Kano S., Honda K., Ohba Y., Mak T.W., Taniguchi T. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005, 434(7030):243-249.
57. Tamura T., Yanai H., Savitsky D., Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 2008, 26:535-584.
58. Thanos D., Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 1995, 83(7):1091-1100.
59. Touzelet O., Loukili N., Pelet T., Fairley D., Curran J., Power U.F. De novo generation of a non-segmented negative strand RNA virus with a bicistronic gene. Virus Res. 2009, 140(1-2):40-48.
60. Wang J.-T., Doong S.-L., Teng S.-C., Lee C.-P., Tsai C.-H., Chen M.-R. Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J. Virol. 2009, 83(4):1856-1869.
61. Wang S.S., Bratti M.C., Rodriguez A.C., Herrero R., Burk R.D., Porras C., Gonzalez P., Sherman M.E., Wacholder S., Lan Z.E., Schiffman M., Chanock S.J., Hildesheim A. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J. Infect. Dis. 2009, 199(1):20-30.
62. Wu L., Fossum E., Joo C.H., Inn K.S., Shin Y.C., Johannsen E., Hutt-Fletcher L.M., Hass J., Jung J.U. Epstein-Barr virus LF2: an antagonist to type I interferon. J. Virol. 2009, 83(2):1140-1146.
63. Xu, Y., Hu, Y., Shi, B., Zhang, X., Wang, J., Zhang, Z., Shen, F., Zhang, Q., Sun, S., and Yuan, Z. in press. HBsAg inhibits TLR9-mediated activation and IFN-[alpha] production in plasmacytoid dendritic cells. Molecular Immunology, Corrected Proof.
64. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288(5467):874-877.
65. Yang H., Ma G., Lin C.H., Orr M., Wathelet M.G. Mechanism for transcriptional synergy between interferon regulatory factor (IRF)-3 and IRF-7 in activation of the interferon-beta gene promoter. Eur. J. Biochem. 2004, 271(18):3693-3703.
66. Yu Y., Wang S.E., Hayward G.S. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 2005, 22(1):59-70.
67. Zacny V.L., Gershburg E., Davis M.G., Biron K.K., Pagano J.S. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1H-benzimidazole. J. Virol. 1999, 73(9):7271-7277.
68. Zhang L., Pagano J.S. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol. Cell. Biol. 1997, 17(10):5748-5757.
69. Zhang L., Pagano J.S. Structure and function of IRF-7. J. Interferon Cytokine Res. 2002, 22(1):95-101.